BIO’s New CEO, Michelle McMurry-Heath, Aims To ‘Change The Dialogue’ Around Science
Executive Summary
Former senior leader in J&J’s medical devices business will take over the reins from Jim Greenwood in June; an immunologist by training, McMurry-Heath brings a resume that is long on scientific, regulatory and corporate experience, but she also has some political qualifications under her belt.
You may also be interested in...
Quick BIO CEO Departure Raises Questions About Direction For Next Leadership Pick
Michelle McMurry-Heath brought a science and regulatory background to the top post of the industry trade group in contrast to the political and lobbying focused careers of her predecessors. Her eventual successor may offer hints as to whether BIO thought that was a successful leadership strategy.
User Fee Renewal Negotiations Beginning This Week
Talks between US FDA and industry to extend the generic drug and prescription drug user fee programs may last into 2021.
Generic Association’s New CEO Signals Focus On Communications
Dan Leonard’s communications background, in addition to his policy expertise, may prove useful for the Association for Accessible Medicines as it navigates ongoing market and public policy challenges.